Who are Nuplazid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Caplyta, Latuda, Fanapt, Remeron, Effexor, Alimix.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pimavanserin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Nuplazid — Competitive Intelligence Brief

Nuplazid (PIMAVANSERIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical Antipsychotic. Area: Neuroscience.

marketed Atypical Antipsychotic 5-hydroxytryptamine receptor 2A Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Nuplazid (PIMAVANSERIN) — Acadia Pharms Inc. Nuplazid works by blocking the action of a specific chemical messenger in the brain called serotonin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nuplazid TARGET	PIMAVANSERIN	Acadia Pharms Inc	marketed	Atypical Antipsychotic	5-hydroxytryptamine receptor 2A	2016-01-01
Caplyta	LUMATEPERONE	Intra-Cellular	marketed	Atypical Antipsychotic [EPC]	5-hydroxytryptamine receptor 2A	2019-01-01
Latuda	LURASIDONE	Sunovion Pharms Inc	marketed	Atypical Antipsychotic	5-hydroxytryptamine receptor 2A	2010-01-01
Fanapt	ILOPERIDONE	Vanda Pharms Inc	marketed	Atypical Antipsychotic [EPC]	5-hydroxytryptamine receptor 2A	2009-01-01
Remeron	mirtazapine	Generic (originally Organon/MSD)	marketed	NaSSA (Noradrenergic and specific serotonergic antidepressant)	5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C	1996-06-14
Effexor	venlafaxine	Generic (originally Wyeth/Pfizer)	marketed	SNRI (Serotonin-norepinephrine reuptake inhibitor)	5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C	1993-12-28
Alimix	CISAPRIDE		marketed	High Risk QT Prolonging Agents	5-hydroxytryptamine receptor 2A	1993-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical Antipsychotic class)

Acadia Pharms Inc · 1 drug in this class
Johnson & Johnson · 1 drug in this class
Sunovion Pharms Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nuplazid — Competitive Intelligence Brief. https://druglandscape.com/ci/pimavanserin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab